Sernova Biotherapeutics Inc
SVA.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.35M | 1.24M | 1.14M | 1.28M | 1.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.68M | 1.56M | 1.73M | 2.55M | 3.04M |
| Operating Income | -1.68M | -1.56M | -1.73M | -2.55M | -3.04M |
| Income Before Tax | -2.36M | -1.77M | -1.62M | -2.95M | -2.63M |
| Income Tax Expenses | -- | -53.10K | -39.60K | 15.40K | 25.90K |
| Earnings from Continuing Operations | -2.36M | -1.72M | -1.58M | -2.97M | -2.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.36M | -1.72M | -1.58M | -2.97M | -2.66M |
| EBIT | -1.68M | -1.56M | -1.73M | -2.55M | -3.04M |
| EBITDA | -1.68M | -1.56M | -1.69M | -2.47M | -3.01M |
| EPS Basic | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 351.12M | 336.40M | 328.71M | 328.48M | 328.48M |
| Average Diluted Shares Outstanding | 351.12M | 336.40M | 328.71M | 328.48M | 328.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |